The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells

被引:120
作者
Yuksel, Aytac [1 ]
Bildik, Gamze [2 ,3 ]
Senbabaoglu, Filiz [2 ,3 ]
Akin, Nazli [2 ,3 ]
Arvas, Macit [1 ]
Unal, Fehmi [4 ]
Kilic, Yagmur [2 ,3 ]
Karanfil, Isil [2 ,3 ]
Eryilmaz, Baldan [2 ,3 ]
Yilmaz, Pelin [2 ,3 ]
Ozkanbas, Can [2 ,3 ]
Taskiran, Cagatay [5 ]
Aksoy, Senai [6 ]
Guzel, Yilmaz [6 ]
Balaban, Basak [6 ]
Ince, Umit [7 ]
Iwase, Akira [8 ]
Urman, Bulent [5 ,6 ]
Oktem, Ozgur [5 ,6 ]
机构
[1] Istanbul Univ, Cerrahpasa Med Sch, Dept OB GYN, Istanbul, Turkey
[2] Koc Univ, Sch Med, Istanbul, Turkey
[3] Grad Sch Hlth Sci, Istanbul, Turkey
[4] Istanbul Teaching & Training Hosp, Dept OB GYN, Istanbul, Turkey
[5] Koc Univ, Sch Med, Dept Obstet & Gynecol, Istanbul, Turkey
[6] Amer Hosp, Womens Hlth Ctr, Comprehens Canc Care & Fertil Preservat Programs, Assisted Reprod Unit, Istanbul, Turkey
[7] Acibadem Univ, Sch Med, Dept Pathol, Istanbul, Turkey
[8] Nagoya Univ, Sch Med, Dept Obstet & Gynecol, Nagoya, Aichi 466, Japan
关键词
gemcitabine; cisplatin; cyclophosphamide; ovary; granulosa cells; cytotoxicity; DOSE-RATE INFUSION; GEMCITABINE; PRESERVATION; GROWTH; AGENTS; DAMAGE; MODEL;
D O I
10.1093/humrep/dev256
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
STUDY QUESTION: Do different chemotherapy drugs exert the same magnitude of cytotoxicity on dormant primordial follicles and the growing follicle fraction in the ovary in vivo and on mitotic non-luteinized and non-mitotic luteinized granulosa cells in vitro? SUMMARY ANSWER: Cyclophosphamide (alkylating agent) and cisplatin (alkylating like) impacted both primordial and pre-antral/antral follicles and both mitotic and non-mitotic granulosa cells, whereas the anti-metabolite cancer drug gemcitabine was detrimental only to pre-antral/antral follicles and mitotic non-luteinized granulosa cells. WHAT IS KNOWN ALREADY: It is already known that anti-metabolite cancer drugs are less detrimental to the ovary than alkylating and alkylating like agents, such as cyclophosphamide and cisplatin. This assumption is largely based on the results of clinical reports showing lower rates of amenorrhea in women receiving anti-metabolite agent-based regimens compared with those treated with the protocols containing an alkylating drug or a platinum compound. But a quantitative comparison of gonadotoxicity with a histomorphometric proof of evidence has not been available for many chemotherapy drugs. Therefore, we combined in this study in vivo and in vitro models of human and rat origin that allows a comparative analysis of the impact of different chemotherapy agents on the ovary and granulosa cells using real-time quantitative cell indices, histomorphometry, steroidogenesis assays, and DNA damage and cell death/viability markers. We also aimed to investigate if there is a difference between mitotic and non-mitotic granulosa cells in terms of their sensitivity to the cytotoxic actions of chemotherapy drugs with different mechanisms of action. This issue has not been addressed previously. STUDY DESIGN, SIZE, DURATION: This translational research study involved in vivo analyses of ovaries in rats and in vitro analyses of granulosa cells of human and rat origin. PARTICIPANTS/MATERIALS, SETTING, METHODS: For the in vivo assays, 54 4- to 6-week old Sprague-Dawley young female rats were randomly allocated into four groups of 13 to receive a single IP injection of: saline (control), gemcitabine (200 mg/kg), cisplatin (50 mg/kg) or cyclophosphamide (200 mg/kg). The animals were euthanized 72 h later. Follicle counts and serum AMH levels were compared between the groups. In vitro cytotoxicity studies were performed using mitotic non-luteinized rat (SIGC) and human (COV434, HGrC1) granulosa cells, and non-mitotic luteinized human (HLGC) granulosa cells. The cells were plated at a density of 5000 cells/well using DMEM-F12 culture media supplemented with 10% FBS. Chemotherapy agents were used at their therapeutic blood concentrations. The growth of mitotic granulosa cells was monitored real-time using xCelligence system. Live/dead cell and apoptosis assays were also carried out using intravital Yo-Pro-1 staining and cleaved caspase-3 expression, respectively. Estradiol (E2), progesterone (P) and anti-Mullerian hormone (AMH) levels were assayed with ELISA. MAIN RESULTS AND THE ROLE OF CHANCE: Cyclophosphamide and cisplatin caused massive atresia of both primordials and growing follicles in the rat ovary whereas gemcitabine impacted pre-antral/antral follicles only. Cyclophosphamide and cisplatin induced apoptosis of both mitotic non-luteinized and non-mitotic luteinized granulosa cells in vitro. By contrast, cytotoxicity of gemcitabine was confined to mitotic non-luteinized granulosa cells. LIMITATIONS, REASONS FOR CAUTION: This study tested only three chemotherapeutic agents. The experimental methodology described here could be applied to other drugs for detailed analysis of their ovarian cytotoxicity. WIDER IMPLICATIONS OF THE FINDINGS: These findings indicate that in vivo and in vitro cytotoxic actions of chemotherapy drugs on the ovarian follicles and granulosa cells vary depending upon the their mechanism of action and the nature of the granulosa cells.
引用
收藏
页码:2926 / 2935
页数:10
相关论文
共 24 条
[1]  
[Anonymous], NAT METHODS, DOI DOI 10.1038/nmeth.f.263
[2]  
Bonetti A, 1996, CLIN CANCER RES, V2, P1829
[3]  
Felici A, 2009, CLIN PHARMACOKINET, V48, P131, DOI 10.2165/0003088-200948020-00005
[4]   Human ovarian follicular development: From activation of resting follicles to preovulatory maturation [J].
Gougeon, A. .
ANNALES D ENDOCRINOLOGIE, 2010, 71 (03) :132-143
[5]   Cyclophosphamide Triggers Follicle Activation and "Burnout"; AS101 Prevents Follicle Loss and Preserves Fertility [J].
Kalich-Philosoph, Lital ;
Roness, Hadassa ;
Carmely, Alon ;
Fishel-Bartal, Michal ;
Ligumsky, Hagai ;
Paglin, Shoshana ;
Wolf, Ido ;
Kanety, Hannah ;
Sredni, Benjamin ;
Meirow, Dror .
SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (185)
[6]   Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model [J].
Laquente, Berta ;
Lacasa, Cristina ;
Ginesta, Mirela M. ;
Casanovas, Oriol ;
Figueras, Agnes ;
Galan, Maica ;
Ribas, Ignacio Garcia ;
Germa, Josep Ramon ;
Capella, Gabriel ;
Vinals, Francesc .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (03) :638-647
[7]   Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters [J].
Mackey, JR ;
Yao, SYM ;
Smith, KM ;
Karpinski, E ;
Baldwin, SA ;
Cass, CE ;
Young, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) :1876-1881
[8]   Cellular pharmacology of gemcitabine [J].
Mini, E. ;
Nobili, S. ;
Caciagli, B. ;
Landini, I. ;
Mazzei, T. .
ANNALS OF ONCOLOGY, 2006, 17 :V7-V12
[9]   Radiosensitization By Gemcitabine Fixed-Dose-Rate Infusion Versus Bolus Injection in a Pancreatic Cancer Model [J].
Morgan, Meredith ;
El Shaikh, Mohamed A. ;
Abu-Isa, Eyad ;
Davis, Mary A. ;
Lawrence, Theodore S. .
TRANSLATIONAL ONCOLOGY, 2008, 1 (01) :44-49
[10]   How do chemotherapeutic agents damage the ovary? [J].
Morgan, S. ;
Anderson, R. A. ;
Gourley, C. ;
Wallace, W. H. ;
Spears, N. .
HUMAN REPRODUCTION UPDATE, 2012, 18 (05) :525-535